Compugen Ltd. (TLV:CGEN)
583.20
-30.70 (-5.00%)
Jun 12, 2025, 5:24 PM IDT
Compugen Revenue
Compugen had revenue of $2.28M USD in the quarter ending March 31, 2025, a decrease of -10.75%. This brings the company's revenue in the last twelve months to $27.59M, down -23.40% year-over-year. In the year 2024, Compugen had annual revenue of $27.86M, down -16.72%.
Revenue (ttm)
$27.59M
Revenue Growth
-23.40%
P/S Ratio
5.37
Revenue / Employee
$372.82K
Employees
74
Market Cap
552.13M ILS
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 27.86M | -5.60M | -16.72% |
Dec 31, 2023 | 33.46M | 25.96M | 346.12% |
Dec 31, 2022 | 7.50M | 1.50M | 25.00% |
Dec 31, 2021 | 6.00M | 4.00M | 200.00% |
Dec 31, 2020 | 2.00M | - | - |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Teva Pharmaceutical Industries | 61.87B |
Danel (Adir Yeoshua) | 2.81B |
Kamada | 622.70M |
Bait Bakfar | 104.50M |
BrainsWay | 161.81M |
SofWave Medical | 235.09M |
Novolog (Pharm-Up 1966) | 2.07B |
Ilex Medical | 922.08M |
Compugen News
- 4 days ago - DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer - Benzinga
- 25 days ago - Compugen Ltd. (CGEN) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 25 days ago - Compugen GAAP EPS of -$0.08, revenue of $2.3M - Seeking Alpha
- 25 days ago - Compugen Reports First Quarter 2025 Results - PRNewsWire
- 4 weeks ago - Compugen Q1 2025 Earnings Preview - Seeking Alpha
- 4 weeks ago - Uncovering Potential: Compugen's Earnings Preview - Benzinga
- 4 weeks ago - Compugen CEO Anat Cohen-Dayag to transition to executive chair - Seeking Alpha
- 4 weeks ago - Compugen Announces Leadership Transitions Effective September 2025 - PRNewsWire